Published in Methods Mol Biol on January 01, 2010
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Forcing form and function: biomechanical regulation of tumor evolution. Trends Cell Biol (2010) 1.77
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat Commun (2013) 1.52
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45
Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) (2010) 1.28
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today (2012) 1.05
Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2. J Biol Chem (2011) 1.02
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage (2011) 0.99
Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem (2012) 0.98
Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. Elife (2015) 0.97
Quantitative interactome analysis reveals a chemoresistant edgotype. Nat Commun (2015) 0.96
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Ovarian cancer stem cells: a new target for cancer therapy. Biomed Res Int (2013) 0.92
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation. DNA Cell Biol (2014) 0.89
Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One (2013) 0.88
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. Pharm Res (2014) 0.88
The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res (2013) 0.86
Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int J Mol Sci (2015) 0.86
YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention. Oncotarget (2011) 0.85
Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Clin Orthop Relat Res (2013) 0.85
Chemoresistance, cancer stem cells, and miRNA influences: the case for neuroblastoma. Anal Cell Pathol (Amst) (2015) 0.85
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer (2014) 0.84
Nanodiamond delivery circumvents tumor resistance to doxorubicin. Acta Pharmacol Sin (2011) 0.82
MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1. Med Sci Monit (2016) 0.82
Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment. Melanoma Res (2011) 0.81
The reversal of antineoplastic drug resistance in cancer cells by β-elemene. Chin J Cancer (2015) 0.80
Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol (2012) 0.80
Transcriptomic insights on the ABC transporter gene family in the salmon louse Caligus rogercresseyi. Parasit Vectors (2015) 0.79
Reaction dynamics of ATP hydrolysis catalyzed by P-glycoprotein. Biochemistry (2014) 0.79
Overexpression of E2F1 in human gastric carcinoma is involved in anti-cancer drug resistance. BMC Cancer (2014) 0.79
Reversal of multidrug resistance by the anti-malaria drug artesunate in the esophageal cancer Eca109/ABCG2 cell line. Oncol Lett (2013) 0.79
mRNA overexpression of BAALC: A novel prognostic factor for pediatric acute lymphoblastic leukemia. Biomed Rep (2015) 0.79
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochem Pharmacol (2013) 0.78
The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicin. Sci Rep (2016) 0.78
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients. J Cancer Res Clin Oncol (2011) 0.78
Reduced Intracellular Drug Accumulation in Drug-Resistant Leukemia Cells is Not Only Solely Due to MDR-Mediated Efflux but also to Decreased Uptake. Front Oncol (2014) 0.78
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm (2012) 0.78
Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. Oncotarget (2016) 0.78
PLK1, A Potential Target for Cancer Therapy. Transl Oncol (2016) 0.77
Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells. Sci Rep (2015) 0.77
Knowing your ABCCs: novel functions of ABCC transporters. J Natl Cancer Inst (2011) 0.77
Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis. BMC Cancer (2016) 0.77
Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. Mol Cell Oncol (2015) 0.77
The impact of cell density and mutations in a model of multidrug resistance in solid tumors. Bull Math Biol (2014) 0.77
Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. World J Urol (2012) 0.77
Pharmacokinetics and drug-interactions determine optimum combination strategies in computational models of cancer evolution. Cancer Res (2017) 0.77
Peroxisome proliferator-activated receptors in regulation of cytochromes P450: new way to overcome multidrug resistance? J Biomed Biotechnol (2012) 0.76
Increased interleukin-6 expression is associated with poor prognosis and acquired cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep (2016) 0.76
Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines. Mol Med Rep (2015) 0.76
Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL. Exp Cell Res (2015) 0.76
Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. Oncotarget (2016) 0.76
Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. Sci Rep (2015) 0.76
The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. PLoS One (2012) 0.76
Mechanisms of drug resistance in colon cancer and its therapeutic strategies. World J Gastroenterol (2016) 0.75
Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Front Bioeng Biotechnol (2015) 0.75
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget (2016) 0.75
Expression of KAP1 in epithelial ovarian cancer and its correlation with drug-resistance. Int J Clin Exp Med (2015) 0.75
Cytotoxicity, antimicrobial and antioxidant activity of eight compounds isolated from Entada abyssinica (Fabaceae). BMC Res Notes (2017) 0.75
Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Oncotarget (2016) 0.75
Predictive value of microparticle-associated tissue factor activity for permeability glycoprotein-mediated multidrug resistance in cancer. Oncol Lett (2016) 0.75
A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors. Biomaterials (2015) 0.75
Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer. Exp Ther Med (2016) 0.75
Modeling intrinsic heterogeneity and growth of cancer cells. J Theor Biol (2014) 0.75
Mitochondrial localization of P-glycoprotein and peptide transporters in corneal epithelial cells--novel strategies for intracellular drug targeting. Exp Eye Res (2012) 0.75
Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget (2016) 0.75
Downregulation of caveolin-1 increases the sensitivity of drug-resistant colorectal cancer HCT116 cells to 5-fluorouracil. Oncol Lett (2016) 0.75
Elevated expression of MDR1 associated with Line-1 hypomethylation in esophageal squamous cell carcinoma. Int J Clin Exp Pathol (2015) 0.75
Targeting Membrane Lipid a Potential Cancer Cure? Front Pharmacol (2017) 0.75
Biodegradable mixed MPEG-SS-2SA/TPGS micelles for triggered intracellular release of paclitaxel and reversing multidrug resistance. Int J Nanomedicine (2016) 0.75
ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling. Respir Res (2017) 0.75
Sulfonation, an underexploited area: from skeletal development to infectious diseases and cancer. Oncotarget (2016) 0.75
Multidrug resistance P-glycoprotein dampens SR-BI cholesteryl ester uptake from high density lipoproteins in human leukemia cells. Am J Cancer Res (2016) 0.75
Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells. Iran Biomed J (2015) 0.75
Tyrphostin RG14620 selectively reverses ABCG2-mediated multidrug resistance in cancer cell lines. Cancer Lett (2017) 0.75
SH003 reverses drug resistance by blocking signal transducer and activator of transcription 3 (STAT3) signaling in breast cancer cells. Biosci Rep (2017) 0.75
Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine. PLoS One (2017) 0.75
Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine. Pharm Res (2017) 0.75
Knockdown of inhibitor of growth protein 2 inhibits cell invasion and enhances chemosensitivity to 5-FU in human gastric cancer cells. Dig Dis Sci (2013) 0.75
Kanglaite inhibits the expression of drug resistance genes through suppressing PVT1 in cisplatin-resistant gastric cancer cells. Exp Ther Med (2017) 0.75
MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma. Mol Ther Nucleic Acids (2017) 0.75
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther (2004) 1.24
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A (2006) 1.18
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol (2004) 1.18
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem (2009) 1.17
Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res (2006) 1.16
The sounds of silence: synonymous mutations affect function. Pharmacogenomics (2007) 1.14
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol (2002) 1.13
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res (2005) 1.12
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux. J Biol Chem (2002) 1.08
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res (2003) 1.08
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res (2009) 1.05
Structure of a multidrug transporter. Nat Biotechnol (2009) 1.04
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res (2013) 1.04
Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. J Cell Physiol (2005) 1.04
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03
Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol (2004) 1.01
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Res (2012) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends Pharmacol Sci (2005) 0.98
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells (2012) 0.95
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics (2007) 0.93
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem (2005) 0.91
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther (2003) 0.91
In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther (2002) 0.90
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol (2006) 0.90
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Drug Resist Updat (2012) 0.90
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem (2011) 0.89
P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res (2007) 0.89
A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem (2004) 0.89
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem (2011) 0.88
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. Biotechniques (2004) 0.88
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol (2010) 0.88
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr Pharm Biotechnol (2004) 0.87
RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res (2011) 0.87
Mouse mammary tumor virus Env-derived peptide associates with nucleolar targets in lymphoma, mammary carcinoma, and human breast cancer. Cancer Res (2005) 0.86
The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res (2013) 0.86
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm (2006) 0.84
Pseudovirions as vehicles for the delivery of siRNA. Pharm Res (2009) 0.84
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Exp Cell Res (2004) 0.84
Factors that limit positron emission tomography imaging of p-glycoprotein density at the blood-brain barrier. Mol Pharm (2013) 0.82
Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. Mol Pharm (2014) 0.81
The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol (2009) 0.81
Outcomes From the NIH Clinical Research Training Program: A Mentored Research Experience to Enhance Career Development of Clinician-Scientists. Acad Med (2016) 0.81
Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv (2004) 0.80
Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A (2002) 0.80
Useful tool to generate unidirectional deletion vectors by utilizing the star activity of BamHI in an NcoI-BamHI-XhoI cassette. Biotechniques (2005) 0.79
Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. J Gene Med (2003) 0.79
An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv (2004) 0.79
Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum Gene Ther (2005) 0.79
Modulation by the ATP/GTP ratio of the phosphorylation level of P-glycoprotein and of various plasma membrane proteins of KB-V1 multidrug resistant cells. Anticancer Res (2003) 0.78
P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway. Biochem Pharmacol (2013) 0.78
Disruption of microfilaments by cytochalasin B decreases accumulation of cisplatin in human epidermal carcinoma and liver carcinoma cell lines. Cancer Chemother Pharmacol (2008) 0.78
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp Cell Res (2012) 0.78
Down-regulation and altered localization of gamma-catenin in cisplatin-resistant adenocarcinoma cells. Mol Pharmacol (2004) 0.78
The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance. Cancer Biol Ther (2004) 0.78
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm (2012) 0.78
Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye. Clin Exp Metastasis (2012) 0.78